This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Haynes, L. M.
Right arrow Articles by Tripp, R. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Haynes, L. M.
Right arrow Articles by Tripp, R. A.

 Previous Article  |  Next Article 

Journal of Virology, July 2002, p. 6873-6881, Vol. 76, No. 14
0022-538X/02/$04.00+0     DOI: 10.1128/JVI.76.14.6873-6881.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.

Neutralizing Anti-F Glycoprotein and Anti-Substance P Antibody Treatment Effectively Reduces Infection and Inflammation Associated with Respiratory Syncytial Virus Infection

Lia M. Haynes,1 Joelyn Tonkin,1,2 Larry J. Anderson,1 and Ralph A. Tripp1*

Respiratory and Enteric Virus Branch, Division of Viral and Rickettsial Diseases, National Center for Infectious Diseases,1 Rollins School of Public Health, Emory University, Atlanta, Georgia 303332

Received 24 January 2002/ Accepted 12 April 2002

Respiratory syncytial virus (RSV) is the most important virus mediating lower respiratory tract illness in infants and young children. RSV infection is associated with pulmonary inflammation and increased levels of substance P (SP), making the airways and leukocytes that express SP receptors susceptible to the proinflammatory effects of this peptide. This study examines combining neutralizing anti-F glycoprotein and anti-SP antibody treatment of RSV-infected BALB/c mice to inhibit RSV replication and inflammation associated with infection. BALB/c mice were prophylactically treated with antibody prior to RSV infection or were therapeutically treated at day 2 or 6 post-RSV infection. Prophylactic or therapeutic treatment with anti-SP antibodies promptly reduced pulmonary inflammatory cell infiltration and decreased the number of cells expressing proinflammatory cytokines, while anti-F antibody treatment reduced virus titers. The results suggest that combined anti-viral and anti-SP antibody treatment may be effective in treating RSV disease.

* Corresponding author. Mailing address: Respiratory Enteric Virology Branch, Division of Viral and Rickettsial Diseases, National Centers for Infectious Disease, 1600 Clifton Rd., NE, Mailstop G-09, Atlanta, GA 30333. Phone: (404) 639-0753. Fax: (404) 639-4005. E-mail: rgt3{at}cdc.gov.

Journal of Virology, July 2002, p. 6873-6881, Vol. 76, No. 14
0022-538X/02/$04.00+0     DOI: 10.1128/JVI.76.14.6873-6881.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Miao, C., Radu, G. U., Caidi, H., Tripp, R. A., Anderson, L. J., Haynes, L. M. (2009). Treatment with respiratory syncytial virus G glycoprotein monoclonal antibody or F(ab')2 components mediates reduced pulmonary inflammation in mice. J. Gen. Virol. 90: 1119-1123 [Abstract] [Full Text]  
  • Eckardt-Michel, J., Lorek, M., Baxmann, D., Grunwald, T., Keil, G. M., Zimmer, G. (2008). The Fusion Protein of Respiratory Syncytial Virus Triggers p53-Dependent Apoptosis. J. Virol. 82: 3236-3249 [Abstract] [Full Text]  
  • Dakhama, A., Park, J.-W., Taube, C., El Gazzar, M., Kodama, T., Miyahara, N., Takeda, K., Kanehiro, A., Balhorn, A., Joetham, A., Loader, J. E., Larsen, G. L., Gelfand, E. W. (2005). Alteration of airway neuropeptide expression and development of airway hyperresponsiveness following respiratory syncytial virus infection. Am. J. Physiol. Lung Cell. Mol. Physiol. 288: L761-L770 [Abstract] [Full Text]  
  • Mejias, A., Chavez-Bueno, S., Rios, A. M., Saavedra-Lozano, J., Fonseca Aten, M., Hatfield, J., Kapur, P., Gomez, A. M., Jafri, H. S., Ramilo, O. (2004). Anti-Respiratory Syncytial Virus (RSV) Neutralizing Antibody Decreases Lung Inflammation, Airway Obstruction, and Airway Hyperresponsiveness in a Murine RSV Model. Antimicrob. Agents Chemother. 48: 1811-1822 [Abstract] [Full Text]  
  • Zimmer, G., Rohn, M., McGregor, G. P., Schemann, M., Conzelmann, K.-K., Herrler, G. (2003). Virokinin, a Bioactive Peptide of the Tachykinin Family, Is Released from the Fusion Protein of Bovine Respiratory Syncytial Virus. J. Biol. Chem. 278: 46854-46861 [Abstract] [Full Text]  
  • Haynes, L. M., Jones, L. P., Barskey, A., Anderson, L. J., Tripp, R. A. (2003). Enhanced Disease and Pulmonary Eosinophilia Associated with Formalin-Inactivated Respiratory Syncytial Virus Vaccination Are Linked to G Glycoprotein CX3C-CX3CR1 Interaction and Expression of Substance P. J. Virol. 77: 9831-9844 [Abstract] [Full Text]  
  • Tripp, R. A., Dakhama, A., Jones, L. P., Barskey, A., Gelfand, E. W., Anderson, L. J. (2003). The G Glycoprotein of Respiratory Syncytial Virus Depresses Respiratory Rates through the CX3C Motif and Substance P. J. Virol. 77: 6580-6584 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»